Business Wire

CHTF

6.8.2024 03:01:29 CEST | Business Wire | Press release

Share
CHTF2024 to Drive Exponential Growth for Exhibitors Through Global Buyer Focus

The 26th China Hi-tech Fair (CHTF2024) will take place on November 14-16, 2024 in Shenzhen China. This year’s fair promises to be a groundbreaking event, covering approximately 400,000m2 and attracting over 5,000 renowned enterprises and international organizations from more than 100 countries and regions. CHTF2024 will feature multiple exhibition zones covering AI and robotics, clean energy, high-end medical devices, China’s leading heavy equipment, top tech industry chains, etc.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802870555/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Global Buyer Invitation Programme of the 26th China Hi-tech Fair (CHTF2024) (Graphic: Business Wire)

China has solidified its position as a global technology powerhouse, with significant advancements in AI, big data, 5G, and clean energy. CHTF serves as a vital platform for debuting innovations and facilitating exchanges. In 2024, the ultimate platform invites global powerful exhibitors to win business for innovation in China’s huge tech market.

To ensure the maximum value for exhibitors, buyers, and visitors, CHTF has launched a comprehensive Global Buyer Invitation Programme, which will invite nearly 500 international buyer delegations from Europe, America, Southeast Asia, the Middle East, and other regions. The anticipated 500,000 professional visitors will create an unparalleled opportunity for business growth and networking.

Key Highlights of The Programme:

  • International and Domestic Buyer Delegations: The event collaborates with prestigious buyer delegations formed by state-owned enterprises, industry leaders, and international corporations, including PetroChina (CNPC), China National Offshore Oil Corporation (CNOOC), CIPR-The conference “Digitalization of Industrial Russia”, Australian Trade & Investment Commission, etc.
  • Tailored Matchmaking: Customized procurement matchmaking events and industry-specific conferences will be held to cater to the precise needs of domestic and international buyers.
  • Extensive Buyer Outreach: The organizer will collect the specific procurement requirements of high-quality buyers in advance and meticulously select qualified exhibitors to ensure that the matchmaking process is precise and effective.
  • Exclusive Buyer Benefits: The registered purchasers can enjoy a range of perks, including VIP privileges, streamlined entry, pre-arranged meetings with exhibitors, complimentary gifts and meals, transportation, and hotel accommodations, and additionally, a chance of lucky draw for signing contracts on-site. (Buyer benefits are subject to change without notice. Please consult the organizer for details.)

With unwavering Shenzhen government backing, extensive industry support, and proven track records of success, CHTF2024 is poised to be the premier destination to explore cutting-edge technologies, foster business collaborations, and contribute to the future of global industries.

Exhibitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/exhibit-apply.html?EID=E0000000413&target=4&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index

Visitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/vistor-register.html?EID=E0000000413&target=1&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index

Follow us on Facebook/LinkedIn/X for updates.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240802870555/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye